Background: The introduction of adjuvant treatment with immune checkpoint inhibitors (ICI) and BRAF/MEK inhibitors has significantly improved recurrence-free (RFS) and distant metastasis-free survival (DMFS) for melanoma patients... ...

请注册登录后继续浏览